To examine the effect of diazoxide on hypoxia-induced soluble fms-like tyrosin kinase-1 (sFlt-1) release in JEG-3 choriocarcinoma cells. Methods: Cells were cultured under normoxia (20% O 2 ) or hypoxia (1% O 2 ), and expression of sFlt-1 mRNA and protein release was determined by quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) assays and enzyme-linked immunosorbent assay (ELISA). Results: Tumor necrosis factor-alpha (TNF-α) as well as hypoxia stimulated sFlt-1 release and diazoxide inhibited both of them. 
Vascular endothelial growth factor (VEGF) is a key angiogenic factor in both physiological and pathological conditions. VEGF exists in five isoforms, generated by alternate splicing of the mRNA to give proteins of 121, 145, 165, 189 and 206 amino acids in length. 1 VEGF exerts its effects by binding with high affinity to two tyrosine kinase receptors VEGFR1/fms-like tyrosine kinase 1 (Flt-1) 2 and VEGFR2/kinase domain receptor (KDR). 3 The two tyrosine kinase receptors VEGFR1/Flt-1 and VEGFR2/KDR were originally thought to be endothelial cell specific. However, in the placenta both endothelial and non-endothelial cells express the VEGF receptors. Both Flt-1 and KDR are expressed by human placental villous endothelium 4~6 and Flt-1 mRNA has also been demonstrated to be highly expressed in the cytotrophoblast shell and columns 7 while the protein localizes to the trophoblast bilayer and extravillous trophoblast. 8 In contrast to the VEGFR2, the VEGFR1 can also be expressed as soluble protein. Soluble Flt-1 (sFlt-1) which comprises the first six immunoglobulin (Ig)-like domains of the protein and is a result of differential splicing of the Flt-1 gene. 9 The existence of naturally occurring sFlt-1 was first demonstrated in cultured human umbilical vein endothelial cells. 9, 10 The trophoblasts also produce large amounts of sFlt 11 and a rise in VEGF binding protein was reported in pregnancy. 12 Levels of sFlt-1 are elevated in pregnancies complicated with preeclampsia 13~15 and elevated sFlt-1 generated by preeclamptic placenta is responsible for suppressing angiogenesis. 16 Adenoviral delivery of sFlt-1 to pregnant rats mimics the clinical manifestations of preeclampsia15
and introduction of sFlt-1 into pregnant mice caused hypertension and proteinuria, which could be reversed by VEGF. 17 The latter study demonstrated that below a critical threshold level, sFlt-1 failed to elicit preeclamptic-like symptoms. 17 Thus, a therapy that can reduce the circulating levels of free sFlt-1 in women with preeclampsia might alleviate the clinical signs and symptoms.
Pretreatment with mitochondrial adenosine triphosphat (ATP)-sensitive K + channel opener (K ATP ) openers has recently emerged as a promising approach in preserving cellular function in various types of oxidative injuries.
The prototype mitochondrial K ATP opener diazoxide has been found to reduce infarct size in the whole heart, and survival of cardiomyocytes. 18, 19 Mitochondrial K ATP opener is responsible for effective oxidative phosphorylation 20 and regulation of reactive oxygen species (ROS) gene ration 21, 22 in ischemic preconditioning. Xu et al. 23 showed that diazoxide inhibits the production of the proinflammatory cytokines tumor necrosis factor-alpha (TNF-α ) and interleukine-6 (IL-6) by preeclamptic placentas and peripheral blood mononuclear cells in normal pregnancy. Recently, Zeng et al. 24 have revealed that heme oxygenase-1 (HO-1) can be induced by diazoxide to stimulate protective process that attenuates ischemia/reperfusion injury. ROS and proinflammatory cytokines, TNF-α and IL-6 have been implicated as strong inducers of sFlt-1 release, whereas HO-1 has been reported to attenuate hypoxia-induced sFlt-1 release and oxidative stress. 25 This understanding led us to a hypothesis that diazoxide might attenuate hypoxia-induced sFlt-1 release and oxidative stress, and exert a beneficial effect to alleviate preeclamptic signs and symptoms. To this end, we examined the effect of diazoxide on hypoxia-induced sFlt-1 release in JEG-3 human choriocarcinoma cells and the underlying mechanism was deciphered in relation with up-regulated HO-1 expression.
Materials and Methods 
Measurement of Transendothelial Resistance
Human umbilical vein endothelial cells (HUVECs) were cultured as confluent monolayers in permeable membrane filters. Transendothelial resistance (TER) was measured using transepithelial volt-ohmmeter (EVOM, World Precision Instruments, Sarasota, FL, USA) and chopstick electrodes.
Assay for Nitric Oxide (NO) Synthesis
Synthesis of NO was determined by assay of culture supernatants for nitrite, a stable reaction product of NO and molecular oxygen. Briefly, 400 μ L of culture supernatant was allowed to react with 200 μ L of Griess reagent 26 and incubated at room temperature for 15 min.
The optical density of the assay samples was measured spectrophotometrically at 570 nm. Fresh culture media served as the blank in all experiments. Nitrite concentrations were calculated from a standard curve derived from the reaction of NaNO 2 in the assay mixture.
Western Blot Analysis
HO-1 protein was determined by Western blot analysis.
Total intracellular protein was extracted by 5 times repeated freeze-thaw (F-T) lysis in F-T buffer (600 mM KCl, 20 mM
Tris-Cl, pH 7.8, 20% glycerol, 0.4 mg/mL Pefabloc, 10 μ g/ mL leupeptin, 10 μ g/mL pepstatin, and 5 μ g/mL aprotinin). 
Analysis of Intracellular ROS Generation
The intracellular generation of ROS was measured using 
Data Analysis
Data were presented as means ± SE When necessary, the data were analyzed by one-way analysis of variance followed by Duncans multiple comparison test. A value of P ＜ 0.01 was considered statistically significant.
Results

Stimulation of sFlt-1 mRNA Expression and
Protein Release in Response to Hypoxia and
TNF-α
Hypoxia and/or inflammatory cytokines contribute as triggers to stimulate sFlt-1 release in preeclampsia placenta. 25 We first examined whether the JEG-3 choriocarcinoma cells conserve the basal expression and release of sFlt-1, and responses to hypoxia and the inflammatory cytokine TNF-α .
Quantitative real time PCR and ELISA analyses showed that the JEG-3 cells conserve baseline sFlt-1 mRNA expression and protein release. Cells cultured under hypoxia (1% O 2 ) for 24 h showed 2.1 fold increase in sFlt-1 mRNA expression and 2.7 fold increase in protein release (Fig. 1) .
Incubation of cells with TNF-α also resulted in elevated sFlt-1 mRNA expression (2.4 fold) and protein release (2.6 fold).
We examined whether hypoxic JEG-3 cell-derived sFlt-1 could lead to endothelial dysfunction by observing the effect of conditioned media on HUVEC functions. HUVEC were grown as confluent monolayers on permeable polycarbonate membrane filters and then switched into conditioned media from normoxic and hypoxic cells. HUVECs incubated in hypoxia-conditioned media showed significantly more rapid drop in TER and carbachol-stimulated NO production than
HUVECs incubated in normoxia-conditioned media (Fig. 2 ).
Inhibition of Hypoxia-and TNF-α-induced sFlt-1 Release by Diazoxide
To determine whether diazoxide affects sFlt-1 release, cells were incubated with diazoxide under normoxia and hypoxia for 24 h and sFlt-1 was assayed in the conditioned media. Diazoxide did not affect the baseline sFlt-1 release, whereas it significantly inhibited the hypoxia-stimulated sFlt-1 release. Likewise, TNF-α -induced sFlt release was significantly reduced upon treatment with diazoxide ( Fig. 3) . 
Up-regulation of HO-1 Expression by Diazoxide
Several investigators showed that increased expression of HO-1 might inhibit sFlt-1 release and placental damage.
Hence, we determined whether diazoxide affects the HO-1 expression. qRT-PCR and Western blot analyses showed that hypoxia exhibited reduction in the HO-1 expression, whereas diazoxide not only reversed the hypoxia-induced reduction but up-regulated further the HO-1 expression (Fig. 5) .
Effects of HO-1 Related Molecules
In order to determine whether the effect of diazoxide to inhibit sFlt-1 release under hypoxia is related with the promoted expression of HO-1, we determined the effects of HO-1 related molecules on the sFlt-release. The HO-1 inducer cobalt protoporphyrin (CoPP) 28 and the metabolic product of HO-1, bilirubin 28 mimicked diazoxide to inhibit sFlt-1 release under hypoxia, whereas the HO-1 inhibitor zinc protoporphyrin IX (ZnPP IX) 28 attenuated the effect of diazoxide (Fig. 6) . Similar results were observed in the experiments to determine the effects of diazoxide and the HO-1 related molecules on hypoxia-stimulated production of ROS (Fig. 7) .
Effect of HO-1 siRNA Transfection
Small interfering RNA approaches were used to confirm further the role of HO-1 in the diazoxide-induced inhibition (Fig. 8) . In analogy, in cells transfected with the HO-1 siRNA, diazoxide did not exert any effect on sFlt release and ROS production under hypoxia (Fig. 9 ).
Discussion
The World Health Organization reports 60,000 maternal deaths worldwide annually as a consequence of preeclampsia and near 12% of their babies fail to thrive within the first month. Preeclampsia is responsible for 30% of all premature deliveries and is associated with approximately 4 million intrauterine growth-restricted babies. 29 Moreover, preeclampsia also impacts long term heath. Systematic re view and meta analysis showed that women with preeclampsia are at a two-fold increased risk of developing cardiovascular disease later in life. 30 For several decades there has been an active search for novel agents which might have a therapeutic potential for treating preeclampsia.
However, still the only effective therapy is delivery of the baby and placenta.
The present study raised the possibility that diazoxide by preeclamptic placentas and peripheral blood mononuclear cells. 23 Those proinflammatory cytokines have been implicated as important mediators to initiate or aggravate preeclampsia. 25 In the present study, qRT-PCR and ELISA analyses showed that exposure to hypoxia or proinflammatory cytokine TNF-α stimulated sFlt-1 mRNA expression and protein release (Fig. 1) . Diazoxide did not affect the baseline sFlt-1 release, whereas it significantly inhibited both the hypoxiaand TNF-α -stimulated sFlt-1 mRNA expression and protein release (Fig. 3) . In preeclampsia, poor placentation causes both oxidative and endoplasmic reticulum stress of the placenta. It is believed placental hypoxia stimulates excessive production of sFlt-1, which binds and deactivates circulating VEGF. When maternal endothelium is deprived of VEGF it becomes dysfunctional hence leading to the clinical syndrome of the mother. Although hypoxia is one trigger for release of sFlt-1 from the preeclamptic placenta, inflammatory mechanisms may contribute or even predominate. 25 Stimulation of sFlt-1 expression and release by TNF-α which is comparable with hypoxia-induced stimulation in the present study is consistent with this argument (Fig. 3) . The ability of diazoxide to inhibit both the hypoxia-and TNF-α -induced sFlt-1 release reminded us of the fact that it had already been known as a promising approach to preserve cellular function in various types of oxidative injuries.
Though diazoxide is a selective activator of mitochondrial K ATP , several mitochondrial K + channel-independent effects of diazoxide should be considered. Diazoxide inhibits succinate oxidation 31 and succinate dehydrogenase 32 or inhibit opening of the mitochondrial membrane pore 33 and these may be responsible for its effects. However, in the present study, the selective inhibitor of mitochondrial K ATP 5-HD27
completely reversed the diazoxide-induced inhibition of hypoxia-stimulated sFlt-1 release. Furthermore, the selective opener of mitochondrial BK Ca NS 1619 27 showed similar effect to inhibit the hypoxia-stimulated sFlt-1 release as diazoxide. NS 1619-induced effect was completely reversed in the presence of the mitochondrial BK Ca in hibitor paxilline. 27 These results suggest that opening of mitochondrial K + channels is a crucial process in diazoxide-induced inhibition of sFlt release (Fig. 4) .
One of the potential therapy which has been proven effective in numerous experimental forms of hypertension is the manipulation of the HO-1 pathway. 34~37 HO-1 is hypothesized to attenuate hypertension through multiple pathways. HO-1 produces two bioactive compounds as products of heme metabolism: carbon monoxide (CO) and bilirubin. Bilirubin has been shown in numerous systems to function as a powerful antioxidant. 38, 39 As it is recognized that production of ROS is a major component of varied forms of hypertension, moderate increases in bilirubin could act to decrease overall oxidative stress. CO acts as a potent vasodilator, functioning in a manner similar to endotheliumderived relaxing factor. 40 Of particular interest to preeclampsia, HO-1 and CO have been shown to directly inhibit production of endoglin and interferon-γ -induced secretion of sFlt-1. 41 Additionally, it has been reported that CO derived from HO-1 in vascular smooth muscle could inhibit production of endothelin-1, 42 antagonized the effect of diazoxide (Fig. 6, 7 ). Finally, a small interfering RNA app roach was used to confirm further the role of HO-1 in the diazoxide-induced inhibition of sFlt-1 release and ROS production. In cells transfected with the HO-1 siRNA, diazoxide did not exert any effect on sFlt-1 release and ROS production under hypoxia (Fig. 8,   9 ). These results, taken together, strongly suggest that upregulation of the HO-1 expression is the crucial mechanism responsible for the diazoxide-induced inhibition of the sFlt-1 release and ROS production under hypoxia.
